The Group B Streptococcal Capsular Carbohydrate: Immune Response and Molecular Mimicry

  • Robert G. Feldman
  • Ger T. Rijkers
  • Maaike E. Hamel
  • S. David
  • Ben J. M. Zegers
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 435)


The group B streptococcus (GBS) is the commonest cause of lethal bacterial infection in the newborn infant.1 GBS possesses a sialylated carbohydrate capsule which is known to be a major virulence factor.2 Mutant GBS which have a non-sialylated capsule are considerably less virulent, fix complement to a greater degree than the isogenic wild type and are more avidly opsonophagocytosed by polymorhonucleoctes.2 Antibodies to GBS capsule have been shown to be protective but the majority of the population do not possess these antibodies. For example, 90% of the population lack antibodies to the type III capsule of GBS (GBS III).3 Furthermore, 60% of seronegative individuals do not respond to experimental vaccination with purified GBS III.4 There has been considerable interest over the last few years in the development of a vaccine which would prevent neonatal infection with GBS. An appropriate approach would seem to be to conjugate the capsular carbohydrates to proteins as has been successfully achieved for Haemophilus influenzae serotype b. It is envisaged that any such vaccine would be given early in pregnancy and the vaccine induced IgG would subsequently be placentally transported to the fetus. In order to facilitate the development of these new vaccines, it is important to understand the basis of the poor immune response to the native capsular carbohydrate in humans and to document the naturally occurring human antibody response.


Sialic Acid Royal Postgraduate Medical School Antibody Avidity Seronegative Donor Poor Immune Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.G. Feldman, Streptococcus agalactiae (group B Streptococcus), in: “Congenital, Perinatal and Neonatal Infections,” A. Greenough, J. Osborne, and S. Sutherland, eds., Churchill Livingstone, Edinburgh (1992).Google Scholar
  2. 2.
    M.R. Wessels, C.E. Rubens, V.J. Benedi, and D.L. Kasper, Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule, Proc Natl Acad Sci. 8983:86 (1989).PubMedCrossRefGoogle Scholar
  3. 3.
    C.J. Baker and D.L. Kasper, Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection, N Engl J Med. 753:294 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    C.J. Baker and D.L. Kasper, Vaccination as a measure for prevention of neonatal GBS infection, Antibiot Chemother. 281:35 (1985).PubMedGoogle Scholar
  5. 5.
    H.J. Jennings, K.G. Rosell, and D.L. Kasper, Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus, Can J Biochem. 112:58 (1980).PubMedCrossRefGoogle Scholar
  6. 6.
    M.R. Wessels, V. Pozsgay, D.L. Kasper, and H.J. Jennings, Structure and immunochemistry of an oligosaccharide repeating unit of the capsular polysaccharide of type III group B Streptococcus, J Biol Chem. 8262:262 (1987).PubMedGoogle Scholar
  7. 7.
    H.J. Jennings, C. Lugowski, and D.L. Kasper, Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide, Biochemistry. 4511:20 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    D.L. Kasper, D.K. Goroff, and C.J. Baker, Immunochemical characterization of native polysaccharides from group B streptococcus: the relationship of the type III and group B determinants, J Immunol. 1096:121 (1978).PubMedGoogle Scholar
  9. 9.
    R.G. Feldman, M.E. Hamel, M.A. Breukels, N.F. Concepcion, and B.F. Anthony, Solid-phase antigen density and avidity of antibodies detected in anti-group B streptococcal type III IgG enzyme immunoassays, J Immunol Methods. 37:170 (1994).Google Scholar
  10. 10.
    R.G. Feldman, G.T. Rijkers, and B.J. Zegers, Human B lymphocyte in vitro response to the group B streptococcal type III capsular carbohydrate, Scand J Immunol. 343:37 (1993).PubMedCrossRefGoogle Scholar
  11. 11.
    P.J. Baker, Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes, Infect Immun. 3465:58 (1990).PubMedGoogle Scholar
  12. 12.
    A.W. Griffioen, E.A. Toebes, G.T. Rijkers, F.H. Claas, G. Datema, and B.J. Zegers, The amplifier role of T cells in the human in vitro B cell response to type 4 pneumococcal polysaccharide, Immunol Lett. 265:32 (1992).PubMedCrossRefGoogle Scholar
  13. 13.
    K.R. Oldenburg, D. Loganathan, I.J. Goldstein, P.G. Schultz, and M.A. Gallop, Peptide ligands for a sugar-binding protein isolated from a random peptide library, Proc Natl Acad Sci. 5393:89 (1992).PubMedCrossRefGoogle Scholar
  14. 14.
    R. Hoess, U. Brinkmann, T. Handel, and I. Pastan, Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3, Gene. 43:128 (1993).Google Scholar
  15. 15.
    R.G. Feldman and A. Ferrante, Prevalence of anti-group B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses, J Infect Dis. 883:162 (1990).PubMedCrossRefGoogle Scholar
  16. 16.
    G.C. Mudde, C.J.M. Verberne, K. Groeneveld, and G.C. De Gast, Human tonsil B lymphocyte function I. The proliferative response to Staphylococcus aureus and pokeweed mitogen in relation to surface heavy chains mu and delta, Clin Exp Immunol. 709:56 (1984).PubMedGoogle Scholar
  17. 17.
    K.A. Knisley and L.S. Rodkey, Affinity immunoblotting. High resolution isoelectric focusing analysis of antibody clonotype distribution. J Immunol Methods. 79:95 (1986).Google Scholar
  18. 18.
    W.F. Riesen, F. Skvaril, and D.G. Braun, Natural infection of man with group A streptococci: levels, restriction in class, subclass and type, and clonal appearance of poly-saccharide group-specific antibodies. Scand J Immunol. 383:5 (1976).PubMedCrossRefGoogle Scholar
  19. 19.
    R.J. Morris, Antigen-antibody interactions: how affinity and kinetics affect assay design and selection procedures, in: “Monoclonal antibodies. Production, engineering and clinical application,” M.A. Ritter and H.M. Ladyman, eds., Cambridge University Press, Cambridge (1995).Google Scholar
  20. 20.
    M.G. Scott, D.L. Crimmins, D.W. McCourt, I. Zocher, R. Thiebe, H.G. Zachau, and M.H. Nahm, Clonal characterization of the human IgG antibody repetoire to Haemophilus influenzae type b polysaccharide, J Immunol. 4110:12 (1989).Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Robert G. Feldman
    • 1
    • 2
  • Ger T. Rijkers
    • 2
  • Maaike E. Hamel
    • 2
  • S. David
    • 2
  • Ben J. M. Zegers
    • 2
  1. 1.Department of Infectious DiseasesRoyal Postgraduate Medical SchoolLondonUK
  2. 2.Department of Immunology, Het Wilhelmina KinderziekenhuisUniversity Hospital for Children and YouthUtrechtThe Netherlands

Personalised recommendations